Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacific Biosciences sees strong Revio demand driving revenue growth

PACB reported a revenue decrease in Q4 2022 but saw strong customer interest in the Revio system, driving revenue growth expectations for 2023. The company is strategically focused on Revio adoption, Onso's performance, and managing market challenges. Opportunities exist in scaling manufacturing capacity, expanding customer reach, and leveraging high demand for Revio and Onso.

PacBio surpasses revenue expectations with strong Revio demand

PacBio's Q1 2023 performance exceeded expectations with record revenue and strong Revio demand, setting up growth opportunities.
While facing challenges in gross margin and operating expenses, PacBio's innovative approach and broad market appeal position it well for the future.
With a focus on margin expansion, consumables growth, and balancing product demand, PacBio aims for sustained profitability and market leadership.
The successful Revio launch and strong China business highlight PacBio's potential for long-term growth and market impact.

PacBio reports record Q2 revenue, eyes market gains and gross margin improvements

PacBio's Q2 performance marked by record revenue, strategic acquisitions, and strong guidance update for 2023 growth.
Focus on Revio system adoption, consumables pull-through, and backlog reduction positions the company for sustained success.
Challenges include market competition, sustaining growth post-upgrade cycle, and addressing validation issues for new products.
Opportunities lie in market shifts towards long reads, improving gross margins through product mix changes, and expanding market access.

PacBio reports record Q3 revenue growth and strategic advancements

PacBio delivered robust performance in Q3, achieving record revenue and strong growth, driven by increased demand for Revio systems and consumables.
While facing challenges such as budget constraints and macroeconomic uncertainties, PacBio's strategic strengths lie in product innovation, market expansion, and financial stability.
Opportunities abound in collaborations, technology enhancements, and market growth, positioning PacBio for continued success and leadership in the genomics industry.
With a positive outlook for future revenue growth, PacBio remains focused on driving innovation, expanding its customer base, and navigating market challenges.

Pacific Biosciences reports robust 2023 performance and eyes growth

PACB had a strong 2023 with revenue growth and successful Revio adoption, despite challenges in China impacting placements.
New kits, software updates, and positive customer feedback on platforms indicate market acceptance and drive customer enthusiasm.
Strategic priorities for 2024 focus on expansion, technology development, and revenue growth, with opportunities in clinical markets and alternative business models.

Pacific Biosciences reports Q2 revenue below expectations, focuses on growth

Pacific Biosciences of California reported Q2 revenue below expectations but showed strength in consumable revenue growth. The company is focused on reducing expenses, improving cash burn, and driving instrument placements. Despite challenges, there are opportunities for growth through attractive deals and positive outlook for consumables.
The company's performance in Q2 reflects ongoing efforts to improve margins and drive revenue growth. Challenges in revenue expectations and headwinds are being addressed through cost reductions and strategic initiatives. Pacific Biosciences remains confident in its progress and future prospects.
With a focus on cost reduction, revenue improvement, and strategic priorities, Pacific Biosciences aims to achieve cash flow positivity by 2026. The company's strengths lie in consumable revenue growth, successful marketing events, and confidence in its product pipeline. Challenges in revenue and cash flow are being managed with opportunities for growth through instrument placements and deals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

World Class Team Will Provide Strategic Guidance and Direction for PacBio's Research and Development Activities MENLO PARK, Calif. , Nov. 2, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it is bringing together a group of scientific experts to form PacBio's Scientific Advisory Board (SAB).

PacBio Announces that Euan Ashley, M.D., Ph.D., Joseph Puglisi, Ph.D.

Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revio to Dramatically Increase Throughput and Lower Cost  While Leveraging the Power of HiFi for Exceptional Accuracy and Direct Methylation Detection MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology.

PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000

The Onso Sequencing System is Designed to Deliver Industry-Leading Sensitivity and Specificity for Novel Insights in Oncology and Disease Research MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onso™ sequencing system.

PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform

Withdraws Guidance with New Product Announcement MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m.

PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15

PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.

PacBio's (PACB) Latest Offering to Enhance Genome Sequencing

PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.

PacBio's (PACB) Latest Offering to Enhance Disease Discoveries

MAS-Seq Supports Isoform Research Using Single-Cell RNA Sequencing from 10x Genomics MENLO PARK, Calif. , Oct. 20, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the launch of its Multiplexed Arrays Sequencing (MAS-Seq) kit in partnership with the Broad Institute of MIT and Harvard and 10x Genomics, Inc. The kit is a first-of-its-kind kitted solution leveraging 10x Genomics' Single Cell Gene Expression technology to enable cost-effective long-read single-cell RNA sequencing for a more complete interrogation of the transcriptome.

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

Alliance panels include a 50-gene pharmacogenomics panel and a nearly 400-gene panel of challenging, medically relevant "dark genes" developed in collaboration with leading institutions MENLO PARK, Calif. and SOUTH SAN FRANCISCO , Oct. 19, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of an initial portfolio of off-the-shelf long-read gene panels.

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

The Consortium Will Build a Publicly Available Database as a Resource to Accelerate Insights from Long-Read Human Genome Datasets MENLO PARK, Calif. , Oct. 18, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the Consortium for Long Read Sequencing (CoLoRS) that aims to accelerate the utility of long-read human genome datasets.

PacBio Collaborates with Leading Researchers to Establish Long-Read Variant Frequency Consortium

PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.

PacBio's (PACB) New Method for TR Profiling Now Available

Analysis Method Supports Research on the Genetic Causes of Common Diseases MENLO PARK, Calif. , Sept. 27, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of a new computational analysis method for profiling more than a million tandem repeats (TRs) across the human genome using PacBio's native long-read HiFi sequencing data.

PacBio Unveils a New Method for Comprehensive, Genome-wide Tandem Repeat Analysis

Avantor Inc.

PerkinElmer

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

U.S. Market Faces Worst Meltdown Since 2020: Here's Why

MENLO PARK, Calif. , Sept. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

PacBio to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Source: motorolka / Shutterstock.com Various biotech stocks are in focus today, but Pacific Biosciences (NASDAQ: PACB ) is one of the more notable names investors are watching right now. At the time of this writing, PACB stock is up 5% amid growing speculative interest in the sector.

Why Is Pacific Biosciences (PACB) Stock Up 5% Today?

ARK Innovation ETF

Exact Sciences

Markforged Holding Corp

Personalis Inc

Teladoc

Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.

5 Top Stocks Cathie Wood Bought This Week

MENLO PARK, Calif. , Aug. 5, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

PacBio to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag

The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Pacific Biosciences (PACB) Climb 261% to Reach the Level Wall Street Analysts Expect?

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Todd Friedman – Director of Investor Relations Christian Henry – President and Chief Executive Officer Susan Kim – Chief Financial Officer Conference Call Participants Kyle Mikson – Canaccord Tejas Savant – Morgan Stanley Dan Brennan – Cowen Operator Welcome to the PacBio's Second Quarter Fiscal Year 2022 Earnings Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc's (PACB) CEO Christian Henry on Q2 2022 Results - Earnings Call Transcript

MENLO PARK, Calif. , Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022.

PacBio Announces Second Quarter 2022 Financial Results

Pacific Biosciences of California "PacBio" is a prime candidate for the "Bio Boom" Portfolio in my Compounding Healthcare Seeking Alpha Marketplace Service. I discuss how PACB meets the criteria. PacBio's HiFi and SMRT sequencing technology continues to fuel growth. The company believes they are on track to hit their full-year revenue guidance of around $160M-$170M.

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

MENLO PARK, Calif. , July 21, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022.

PacBio Announces Appointment of Genomics Industry Veteran Jeff Eidel as Chief Commercial Officer

MENLO PARK, Calif. , July 18, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2022 financial results on Wednesday, August 3, 2022, at 5:00 pm Eastern Time.

PacBio to Report Second Quarter 2022 Financial Results on August 3, 2022

Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health Genomics Veteran to Lead Company Which Has a Commercial-Ready Novel Technology Platform that Can Realize the Largely Untapped Contribution of Epigenetics to Human Health

Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer

Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing

News for Pacific Biosciences of California Stock (PACB)